title: Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapy.
abstract: As predictive testing for Parkinson's disease (PD) becomes available, it will be important to understand in whom such testing will be used. To address this issue, we conducted a mail survey of 138 first-degree relatives of PD patients. In the absence of treatment, 60% reported that they would either "definitely" or "probably" be interested in predictive testing. In the setting of a clinical trial, this number increased to 71% (p=0.04) and when neuroprotective therapy is available, interest increased to 90% (p<0.001). Interest in predictive testing for PD is moderate in the absence of effective therapy, and goes up significantly when both clinical trial participation and neuroprotective therapy are offered.
authors: Department of Neurology, Pennsylvania Hospital, University of Pennsylvania, USA. nabila.dahodwala@uphs.upenn.edu
authors: N
authors: N
authors: Dahodwala
authors: J
authors: J
authors: Connolly
authors: J
authors: J
authors: Farmer
authors: M B
authors: MB
authors: Stern
authors: D
authors: D
authors: Jennings
authors: A
authors: A
authors: Siderowf
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D034742:Electronic Mail / Q000706:statistics & numerical data; D005190:Family; D005260:Female; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D011237:Predictive Value of Tests; D012189:Retrospective Studies
chemical_list: D018696:Neuroprotective Agents